Brussels, 19/04/2007 (Agence Europe) - No fewer than 159 amendments have been brought forward ahead of the first reading in the European Parliament of the draft regulation on a centralised authorisation procedure for the marketing of medicines derived from cell and tissue engineering. All the signs point to a hard-fought battle next week in Strasbourg between the supporters of a European mechanism to control the quality and safety of the products which could help patients throughout the EU,...